A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS

Overview of attention for article published in Neurotherapeutics, July 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

twitter: 13 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 11 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 13 X posts from 13 X users, with an upper bound of 51,127 followers.

RT @AaronBosterMD: A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine,…

20 Aug 2023

Reply Repost Favourite

A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS https://t.co/ubGqZB1j3A

16 Aug 2023

Reply Repost Favourite

Urgent need for novel neuroreparative & neuroprotective immune modulating therapies. Phase1b study: assess safety & tolerability of ascending #liothyronine doses in indivs w/#MS; assess effect on clinical disability & #HRQOL. @Calabre04804429 @

25 Jul 2023

Reply Repost Favourite

Ty, @MStranslate 🙏😘@SammyJoLDN

20 Jul 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 9 additional X posts.